Skip to main content
Equibles
ARCT logo

ARCT · Arcturus Therapeutics Holdings Inc.

Track ARCT — free

Use ARCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.73 +0.75 (+5.36%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$418.67M
Shares
28.42M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.73 Open$14.06 Day$14.06–15.12 52W close$5.53–23.16 Avg vol 30d1.2M Short int6.1M · 21.5% float · 3.1d Short vol56% Last earningsAug 6, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 8 wks
Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$29.37M
Trailing 12 months
Net income (TTM)
−$93.28M
Trailing 12 months
Revenue growth YoY
-89.5%
Year over year
Operating margin
-348.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.8%
Year over year · more shares
Price change (1Y)
-18.3%
Trailing year
Short interest
21.5%
Latest settlement · 3.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +86%
above
Price vs 50-day avg +57%
above
RSI (14) 62
neutral
MACD trend Negative
52-week position 52%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +87%
trailing
6-month return +122%
trailing
YTD return +140%
this year
Relative strength +104%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
21.45% of float · ▼ -6.6% MoM · 3.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
136 holders — mid 3-yr range
Squeeze score 77
high risk · 0–100
Fundamentals
Fair
Revenue growth −46%
Y/Y
EPS growth +20%
Y/Y
Free cash flow $-74.5M
Balance sheet $355.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −76%
past year
ATR 8.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+86% Bullish
Price vs 50-day avg
+57% Bullish
RSI (14)
62 Neutral
MACD trend
Negative Bearish
52-week position
52% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
21.45% of float · ▼ -6.6% MoM · 3.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
136 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6 Now $15 · 52% Range high $23
vs 200-day avg +86% vs 50-day avg +57%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ARCT
Arcturus Therapeutics Holdings Inc.
this stock
$418.67M +140.3% -46.1% — 21.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
136
% held
88.0%
Net QoQ
+320.1K sh
Top holder
FEDERATED HERMES, INC.
Held Float
View
Held by Funds
Fund positions
154
View
Short & Settlement
Short Interest Falling
Shares short
6.1M
Days to cover
3.1d
Change
-429.2K sh
View
Short Volume
Short vol %
56%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
5.1K
Value
$40.1K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
36.7%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$82.0M
Net income (FY)
$-65.8M
EPS diluted
$-2.40
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 25, 2026
This year
10
View
Proposed Sales
Value
$249.1K
Shares
12.0K
Filed
Oct 15, 2024
View
Earnings & Events
Earnings Calls
Last call
Aug 31, 2026
View

Performance

5D 20D 120D MTD YTD
ARCT -5.3% +87.4% +122.2% -0.2% +140.3%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -4.2% +89.2% +104.3% +0.2% +128.2%
Key facts CIK 1768224 CUSIP 03969T109 13F (30d) 42 filings 42 filers Visit website Investor relations